We are looking for our first BD hire, to build the company as a member of the leadership team. Know someone - please ask them to get in touch with Paul Bradley-Law https://lnkd.in/e9UrUz6z
About us
An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2021
Employees at Serna Bio
-
Paul Bradley-Law
People and Operations Strategy
-
Neil Kubica
Entrepreneurial leader driven to unlock the full potential of the genome for drug discovery and development
-
Harini Srinivasan
Head of Platform Biology at Serna Bio
-
Josephine Joel
Principal Scientist | Team Leader | Molecular Biologist | AAV Scientist | Project Manager
Updates
-
Serna Bio is a remote-first company spread across two continents. We have carefully designed ways of working which allow us to rapidly progress work in an interdisciplinary, international environment. But every six months we spend a week together to review our progress and plan for the future. The opportunity to connect, celebrate successes, break bread with one another, and Escape (or fail to escape) Rooms is a force accelerator for our work and a highlight of the calendar.
-
A wonderful primer on RNA from the National Human Genome Research Institute. https://lnkd.in/eS-8AKPh
Ribonucleic Acid (RNA) Fact Sheet
genome.gov
-
GARNET (Gtdb Acquired RNa with Environmental Temperatures), a new database for RNA structural and functional analysis anchored to the Genome Taxonomy Database (GTDB) used to drive language models which predict mutations that improve RNA function. Paper by Shulgina et al https://lnkd.in/e_sYQeEA
RNA language models predict mutations that improve RNA function
biorxiv.org
-
"RNA will define a generation of science" New opinion piece in the NYT on the "under-appreciated" potential of RNA: https://lnkd.in/eSddFEa9
Opinion | The Long-Overlooked Molecule That Will Define a Generation of Science
https://www.nytimes.com
-
Enlightening article from Scientific American about how RNA may be ruling our genome: https://lnkd.in/ehbsN3TK
The RNA Revolution Is Changing Our Understanding of Biology
scientificamerican.com
-
Tomorrow our CEO Rabia T. K. will be at the RNA Medicine and Innovation in Montreal (RMedI) Symposium sharing insights about our work mapping the Druggable Transcriptome. You can register here https://lnkd.in/ejaJRuNh
RNA Medicine and Innovation Symposium
ircm.qc.ca
-
On Wednesday, Carson J Bryant - Senior Data Scientist at Serna Bio, will speak at #LCSE2024 about his pathway from academia to industry and offer guidance for early career professionals on building a career in Biotech startups. It will be highly valuable listening for anyone looking to move into industry and startups in particular. You can register for online tickets here: https://lnkd.in/gz7YA_T3
LSCE 2024
event.fourwaves.com
-
Next week our CEO Rabia T. K. will be presenting at the RNA Medicine & Innovation (RMedI) symposium organised by Martin Sauvageau and Eric Lecuyer at the Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute in downtown Montreal. The meeting, organized in collaboration with the McGill University Centre for RNA Sciences (MCRS) and Université de Montréal, will cover exciting topics in RNA research, including the latest advancements in RNA therapeutics and technologies, cellular mechanisms of RNA regulation and disease implications. Rabia T. K. will speak about RNA Medicine and Innovation as part of the RNA Targeting Modalities stream alongside a stellar lineup of speakers from this space including Amanda Hargrove, Frank Slack, and Masad J. Damha, PhD, FCIC Here's a link to register: https://lnkd.in/gwpQ4cUA
RNA Medicine and Innovation Symposium
ircm.qc.ca
-
"We estimate the probability of success for drug mechanisms with genetic support is 2.6 times greater than those without". A new paper in Nature from Minikel et al refines the impact of genetic evidence on clinical success: https://lnkd.in/edsE4pXd
Refining the impact of genetic evidence on clinical success - Nature
nature.com